Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for INB-100 in Leukemia, Blood cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
8/12/24- Completed Type B meeting. 2/14/25- Reported updated data at TCT 2025. 5/12/25- Presented data at ISCT'25. 10/29/25– Add Ohio State site to accelerate enrollment. 03/12/26:- Expect INB-100 dosing completion early 2026. Plan long-term follow-up Ph1 data at Q4 2026 meeting. 05/07/26:- Reiterated INB-100 dosing completion and long-term follow-up Ph1 results at late 2026 medical meeting. 08/06/26:- Reiterated INB-100 clinical update at a late 2026 scientific meeting.
Verification
Confirm timing and program details against the company announcement or filing.